Regorafenib; 755037-03-7; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(Trifluoromethyl)Phenyl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide; Regorafenibum;

China Regorafenib API Suppliers

Regorafenib is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.

Regorafenib is an oral multi-kinase inhibitor that is used in the therapy of refractory metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumor. Regorafenib has been associated with frequent serum aminotransferase elevations during therapy and with rare, but sometimes severe and even fatal instances of clinically apparent liver injury.

Regorafenib; 755037-03-7; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(Trifluoromethyl)Phenyl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide; Regorafenibum;

Regorafenib API

Regorafenib API CAS 755037-03-7

Regorafenib CAS 755037-03-7 good quality

Regorafenib API CAS 755037-03-7

Regorafenib CAS 755037-03-7 good quality

China Regorafenib API Suppliers